Xenograft, Orthotopic & Syngeneic Models
WBI offers xenograft, orthotopic and syngeneic models for assessment of anti-cancer agents.
Xenograft or Orthotopic Model | |
Species | Athymic nude or SCID mouse; or Athymic nude rat |
Group Size |
5-20 |
Dosing |
|
Readouts | Tumor volume |
Optional Services |
|
Syngeneic Mouse Models | ||
Manipulation of the immune response through administration of immune therapeutics is an active area of cancer treatments. To evaluate potential treatments, a functional immune system in test animals is essential and is available in syngeneic mouse models. Efficacy of test materials is rapidly evaluated within 2-3 weeks of cell implants and initial dosing with test material. | ||
Cancer Type | Cell Line | Mouse Strain |
Breast |
4T1 |
Balb/c |
Colorectal |
CT26 MC38 |
Balb/c C57BL/6 |
Melanoma |
C57BL/6 |
|
Lung |
Lewis Lung |
C57BL/6 |
Pancreas | Pan02 | C57BL/6 |
Cell implantation |
Subcutaneous, intravenous |
|
Controls |
Anti-PD-1 antibody Anti-PD-L1 antibody Anti-CTLA-4 antibody |
|
Readouts |
Tumor volumes measured and reported 3 times weekly with statistical analysis for efficacy. Survival, lung metastasis. |
|
Collections |
Tumors at termination Optional: Plasma (or serum) samples during tumor growth and/or at termination; organs (lymph node, spleen, etc.) Dissociation, cryo-conservation and shipment of tumor cells, lymph node cells, spleen cells |
|
Project scheduling |
Start-up with cell implants within 2 weeks of order Completion within 4 weeks of order. Optional study extension: Re-implant of cancer cells for evaluation of memory T cells |
The following are selected cancer models:
Breast Cancer Models (BT-474 & MDA-MB-231)
Melanoma Models (Syngeneic B16-F10, A375, LOX 1MV1)
Liver Cancer Models (MHCC97H, Huh-7)
Pancreatic Cancer Model (HPAFII)